Comparative Pharmacology
Head-to-head clinical analysis: CIS PYRO versus IODOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS PYRO versus IODOTOPE.
CIS-PYRO vs IODOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cis-pyro is not a recognized pharmaceutical agent. No mechanisms data available.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
Not applicable: CIS-PYRO is a pyrophosphate-based radiopharmaceutical used in cardiac imaging, not a therapeutic drug. Standard adult dose: 555-1110 MBq (15-30 mCi) intravenously once.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (IV); prolonged in renal impairment (up to 30 hours in ESRD).
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
Primarily renal excretion: 65-80% unchanged in urine; biliary/fecal excretion accounts for 15-25%.
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical